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Abstract
Alternative splicing creates several Nav1.5 transcripts in the mammalian myocardium and in various other tissues including
brain, dorsal root ganglia, breast cancer cells as well as neuronal stem cell lines. In total nine Nav1.5 splice variants have
been discovered. Four of them, namely Nav1.5a, Nav1.5c, Nav1.5d, and Nav1.5e, generate functional channels in
heterologous expression systems. The significance of alternatively spliced transcripts for cardiac excitation, in particular their
role in SCN5A channelopathies, is less well understood. In the present study, we systematically investigated
electrophysiological properties of mutant T1620K channels in the background of all known functional Nav1.5 splice
variants in HEK293 cells. This mutation has been previously associated with two distinct cardiac excitation disorders: with
long QT syndrome type 3 (LQT3) and isolated cardiac conduction disease (CCD). When investigating the effect of the T1620K
mutation, we noticed similar channel defects in the background of hNav1.5, hNav1.5a, and hNav1.5c. In contrast, the
hNav1.5d background produced differential effects: In the mutant channel, some gain-of-function features did not emerge,
whereas loss-of-function became more pronounced. In case of hNav1.5e, the neonatal variant of hNav1.5, both the splice
variant itself as well as the corresponding mutant channel showed electrophysiological properties that were distinct from
the wild-type and mutant reference channels, hNav1.5 and T1620K, respectively. In conclusion, our data show that
alternative splicing is a mechanism capable of generating a variety of functionally distinct wild-type and mutant hNav1.5
channels. Thus, the cellular splicing machinery is a potential player affecting genotype-phenotype correlations in SCN5A
channelopathies.
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Introduction
Voltage-gated sodium (Na
+) channels mediate the fast upstroke
of action potentials in electrically excitable cells by rapidly
increasing the Na
+ permeability [1]. The tetrodotoxin (TTX)
resistant isoform Nav1.5, encoded by the SCN5A gene, is the
predominant isoform in the heart [2,3]. This channel plays a key
role for excitability of atrial and ventricular cardiomyocytes and
for rapid impulse propagation through the specific conduction
system. Mutations in SCN5A can cause a broad variety of
pathophysiological phenotypes, such as long QT syndrome type
3 (LQT3), Brugada syndrome (BrS), cardiac conduction disease
(CCD), or sick sinus syndrome (SSS) [4,5].
Heterologous expression of respective hNav1.5 mutant channels
and electrophysiological measurements often provided a reason-
able explanation for the clinical phenotype. However, remarkable
inconsistencies were noticed in several cases, like a severe disease
manifestation in patients, but only subtle alterations in channel
kinetics [6–8], or asymptomatic mutation carriers, but severely
impaired in vitro channel function [9–12]. Even a broad spectrum
of disease manifestations could be diagnosed in carriers of the
same SCN5A mutation [11,13–16]. Such apparent genotype-
phenotype disassociations are most likely due to experimental
limitations intrinsic to heterologous expression systems. In contrast
to host cells like HEK293 or Xenopus oocytes, cardiomyocytes of
the intact heart can be faced with additional risk factors or
equipped with protective mechanisms capable of compensating for
an impaired Na
+ channel function, thereby aggravating the
phenotype or preventing the onset of the disease in mutant gene
carriers. Apart from known determinants such as gender or ageing
[4,10], risk factors relevant for disease manifestation and cardiac
events could be: a) a deficient interaction with one of the cardiac
proteins modulating hNav1.5 [17], b) polymorphisms in hNav1.5
[18,19] or in other cardiac genes [6], c) a drop of intracellular pH
[20], d) an increased temperature due to a feverish infection [21],
e) drugs and xenobiotics [22,23], f) the cellular phosphorylation
status [24,25], or g) a variable channel expression from the wild-
type versus the mutated allele [26,27].
Another important mechanism affecting genotype-phenotype
correlations in SCN5A channelopathies could be the alternative
splicing of wild-type and mutant Nav1.5 transcripts. To date
totally nine Nav1.5 splice variants have been discovered in various
tissues including heart, brain, dorsal root ganglia, breast cancer
cells, and neuronal stem cells [28]. The abundance of an
individual splice variant, relative to authentic Nav1.5, depends
on the mammalian species, on the tissue, and on the ontogenetic
stage. Although the physiological significance of alternative
splicing of hNav1.5 in the heart and in other tissues is less well
understood, electrophysiological investigations revealed that func-
tional consequences of Nav1.5 splicing are diverse: Spliced
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they can be non-functional (Nav1.5b, Nav1.5f, truncated variants
E28B-D), or their electrophysiological properties can be virtually
unchanged (Nav1.5a, Nav1.5c), when compared to non-spliced
Nav1.5 [28].
In the present study we systematically investigated electrophys-
iological properties of a hNav1.5 mutant (T1620K) in the
background of all known functional Nav1.5 splice variants
(Nav1.5a, Nav1.5c, Nav1.5d, Nav1.5e; Fig. 1). This mutation has
been previously associated with two distinct cardiac arrhythmias:
Mutant gene carriers presented with LQT3, an SCN5A channelo-
pathy associated with enhanced Na
+ channel activity, and with
CCD, associated with loss-of-function in the cardiac Na
+ channel
[29]. We have chosen the T1620K mutation in the hope to
observe differential effects on gain-of-function and loss-of-function
properties of T1620K in the background of the distinct splice
variants.
Methods
Expression plasmids
All Na
+ channel variants used in this study are listed in
Table 1. Our original human Nav1 . 5c D N A( h H 1 ;k i n d l y
provided by Dr. George, Vanderbilt University) codes for
glutamine at position 1027 [30], which is considered as a rare
Nav1.5 variation [31]. Therefore, we first introduced an
arginine at this position. Second, we removed Q1077 from the
resulting cDNA variant to obtain the most common hNav1.5
sequence, previously designated as hH1c (AY148488) [31]. This
cDNA was used as wild-type hNav1.5 in the present study
(Table 1). To obtain the T1620K mutant variants, we
introduced lysine at position 1620, as previously described
[29]. Patients of this family also presented with polymorphism
H558R on the same allele (Fig. 1) [29]. Therefore, we
introduced an arginine at this position in all T1620K cDNA
variants, similarly as previously described [29]. The polymor-
phism H558R had no effect on the electrophysiological
properties of hNav1.5 and mutant T1620K channels [18,29].
All sequence deletions (complete exon 18, partial exon 17,
DQ1077), point mutations (positions 558, 1027, 1077, and
1620), as well as the modifications at 7 positions in adult exon
6b, leading to the corresponding neonatal exon 6a sequence
[32,33], were done by recombinant PCR using suitable
mutagenesis primers and a thermostable DNA polymerase with
proofreading activity (Pfu DNA polymerase, Promega, Madison,
USA), according to previously described experimental proce-
dures [29,34,35]. The correctness of PCR derived sequences
was confirmed by DNA sequencing. All channel variants, listed
in Table 1, were placed under the control of the SV40 promoter
in expression plasmid pTSV40G, a derivative of pTracerSV40
(Invitrogen) [34]. Vector pTSV40G contains the coding region
of the enhanced green fluorescent protein (EGFP; Clontech) in a
separate expression cassette to allow for selection of transfected
cells.
Heterologous expression in HEK293 cells
Human embryonic kidney cell line (HEK293 cell line, ATCC
number CRL-1573, supplied by the Centre for Applied Micro-
biology and Research, Salisbury, Wiltshire, UK) were cultured in
MEM (Gibco BRL) supplemented with 10% fetal bovine serum,
2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 0.25 mg/ml amphotericin B. Cells were transfected by a
standard calcium phosphate precipitation method using 1 to 2 mg
plasmid DNA per transfection (60 mm cell culture dishes). After
an incubation time of 24 h, the transfection mixture was removed,
and the cells were seeded onto poly-L-lysine coated glass coverslips
and cultured in fresh growth medium. Currents were investigated
24 to 48 hours after transfection.
Patch-clamp measurements
Electrophysiological recordings were performed with the patch-
clamp technique on the stage of an inverted microscope (Axiovert
100, Carl Zeiss Jena GmbH, Germany) using an Axopatch 200B
amplifier (Axon-Instruments, Foster City, USA). The measure-
ments were carried out at room temperature. The bath solution
contained (mM): 140.0 NaCl, 1.8 CaCl2, 1.0 MgCl2, 10.0 glucose,
10.0 HEPES, pH 7.4 (CsOH). The pipette solution contained
Figure 1. Proposed membrane topology of hNav1.5 splice
variants (A) and representative whole-cell currents through
wild-type hNav1.5 and mutant T1620K channels (B). (A) Four
functional Nav1.5 splice variants have been detected so far: Alternative
splicing can result in skipping of exon 18 (Nav1.5a), in alternative usage
of the exon 18 splice acceptor site and the extension of this exon by a
CAG trinucleotide coding for Q1077 (Nav1.5c), in partial deletion of exon
17 (Nav1.5d), and in the alternative usage of neonatal exon 6a instead of
the adult exon 6b (Nav1.5e) [28]. Incorporation of neonatal exon 6a
modifies the cardiac Na
+ channel at 7 positions [32,33]. Alterations in
kinetics are largely due to the introduction of a positive lysine instead of
an aspartate in the DI/S3S4 linker at position 211 [43]. Abbreviations:
E17 - exon 17 sequence, E18 - exon 18 sequence, EF - EF-hand domain,
IQ - calmodulin binding motif. (B) Representative Na
+ currents
generated by hNav1.5 and mutant T1620K channels in HEK293 cells.
T1620K channels inactivated faster at less depolarized potentials (thick
line), but more slowly at more depolarized potentials (dashed line),
when compared to hNav1.5 (hNav1.5: th 250 mV=4.35 ms, th0 m V =
0.80 ms; T1620K: th 250 mV=1.55 ms, th0m V=0.99 ms; see also Fig. 2B
for the partial loss of the voltage dependency of open-state
inactivation). Other parameters and statistics on both channel types
are given in Fig. 2 and Table 2. Calibration bars indicate 2 ms and 1 nA.
doi:10.1371/journal.pone.0019188.g001
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(CsOH). Currents were elicited by test potentials from -120 mV to
40 mV in 5 or 10 mV increments at a pulsing frequency of
1.0 Hz. We used only cells that produced a peak current
amplitude ,5 nA. Steady-state activation (m‘) was evaluated by
fitting the Boltzmann equation
m?~ 1zexp { V{Vm ðÞ =s ½  ðÞ
{1
to the normalized conductance as function of voltage. Steady-state
inactivation (h‘) was determined with a double-pulse protocol
consisting of 500 ms prepulses to voltages between 2120 and
230 mV followed by a constant test pulse of 10 ms duration to
220 mV at a pulsing frequency of 0.5 Hz. The amplitude of peak
INa during the test pulse was normalized to the maximum peak
current and plotted as function of the prepulse potential. Data
were fitted to the Boltzmann equation
h?~ 1zexp V{Vh ðÞ =s ½  ðÞ
{1:
V is the test potential, Vm and Vh are the mid-activation and
mid-inactivation potentials, respectively, and s the slope factor in
mV. Glass pipettes were pulled from borosilicate glass and their
tips were heat polished by the microforge MF 830 (Narishige,
Japan). The pipette resistance was between 1.5 and 2.5 MV.
Series resistance compensation was adjusted so that any
oscillations were avoided leaving at most 25% of the series
resistance uncompensated. Currents were on-line filtered with a
cut-off frequency of 10 kHz (4-pole Bessel). Recording and
analysis of the data was performed on a personal computer with
the ISO2 software (MFK, Niedernhausen, Germany). The
sampling rate was 50 kHz. Student’s t-test was used to test for
statistical significance. Statistical significance was assumed for
P,0.05.
Table 1. Structure of the Na
+ channel variants used in this study.
Channel variant Exon composition Amino acid at position
Exon 6 variant (205–234) Exon 17 (930–1076) Exon 18 (1078–1130) 558 1027 1077 1620
hNav1.5 adult exon 6b present present H R DQT
T1620K adult exon 6b present present R R DQK
hNav1.5a adult exon 6b present Dexon 18 H R DQT
T1620Ka adult exon 6b present Dexon 18 R R DQK
hNav1.5c adult exon 6b present present H R Q T
T1620Kc adult exon 6b present present R R Q K
hNav1.5d adult exon 6b D961–1000 present H R Q T
T1620Kd adult exon 6b D961–1000 present R R Q K
hNav1.5e neonatal exon 6a present present H R Q T
T1620Ke neonatal exon 6a present present R R Q K
Previously we used the hH1 clone [30] as the reference hNav1.5 sequence to investigate the effect of the T1620K mutation on channel kinetics [29]. The corresponding
protein sequence includes amino acids encoded by exon 6b as well as H558, Q1027, and Q1077. T1620K carriers and unaffected family members presented with R558
and H558, respectively. As shown previously, the polymorphism at this position did not differentially affect channel kinetics [29].
doi:10.1371/journal.pone.0019188.t001
Table 2. Electrophysiological properties of splice variants of hNav1.5 and T1620K channels in HEK293 cells.
Channel Steady-state activation Steady-state inactivation Recovery from inactivation
s (mV) Vm (mV) n s (mV) Vh (mV) n tf (ms) Af ts (ms) As n
hNav1.5 7.560.3 231.461.3 14 6.060.1 288.261.6 14 4.460.3 0.8460.02 80.4617.0 0.1660.02 11
T1620K 7.560.3 235.961.2
# 11 8.360.2
# 299.161.7
# 15 3.160.3
# 0.8460.01 73.2621.3 0.1660.01 11
hNav1.5a 6.860.3 233.261.0 13 6.260.2 283.561.9 14 4.160.3 0.8560.02 61.868.8 0.1560.02 9
T1620Ka 7.160.2 236.760.7
# 32 8.360.2
# 299.361.5
# 32 2.860.2
# 0.8460.01 71.3614.2 0.1660.01 15
hNav1.5c 7.060.1 232.860.3 33 6.260.1 286.360.4 31 4.260.3 0.8560.01 56.568.0 0.1560.01 12
T1620Kc 7.760.2 235.160.8
# 36 8.160.1
# 200.361.3
# 27 2.860.2
# 0.8360.01 68.668.6 0.1760.01 20
hNav1.5d 7.560.2 223.560.7* 60 7.060.2* 285.060.8 34 6.560.5* 0.7560.10 121646 0.2560.10 5
T1620Kd 8.860.2
1# 222.460.8
1 55 9.260.3
1# 299.861.5
# 29 10.061.0
1# 0.7760.01
1 187630
1 0.2360.02
1 16
hNav1.5e 8.360.4 221.360.8* 8 6.060.2 283.861.9 7 4.460.3 0.8160.01 89.9610.5 0.1960.01 25
T1620Ke 8.860.5 226.361.9
1# 88 . 1 60.5
# 2100.961.2
# 63 . 0 60.2
# 0.8260.02 91.4621.0 0.1860.02 10
*Indicates p,0.05 for a hNav1.5 splice variant versus hNav1.5, illustrating alterations caused by alternative splicing of hNav1.5.
1Indicates p,0.05 for a spliced T1620K variant versus T1620K, illustrating alterations caused by alternative splicing of T1620K.
#Indicates p,0.05 for a T1620K variant versus the corresponding hNav1.5 variant, illustrating alterations caused by the T1620K mutation only.
doi:10.1371/journal.pone.0019188.t002
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PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19188Figure 2. Electrophysiological properties of hNav1.5 and mutant T1620K channels. (A) Steady-state activation as function of voltage. (B)
Time constants of inactivation as function of voltage. The Na
+ current decay was fitted with a monoexponential function. (C) Steady-state inactivation
as function of voltage. (D) Recovery from inactivation. (E) Illustration of the window current in hNav1.5 (light gray) and T1620K (dark gray). Due to the
hyperpolarizing shift of steady-state activation (A) and the increased slope of the steady-state inactivation curve (C) both the amplitude and the
voltage range of the window current is increased. Gain-of-function features, most likely resulting in prolonged ventricular action potentials and thus
in LQT3, are the slower current decay at potentials positive to 240 mV (B), the faster recovery from inactivation (D), and the larger window current (E)
[5,29]. Loss-of-function features, most likely resulting in conduction slowing and thus in CCD, are the faster current decay at potentials negative to
240 mV (B), and the reduced steady-state availability at the resting membrane potential (C) [5,29]. Individual curves illustrating steady-state
activation (A), steady-state inactivation (C), and recovery from inactivation (D) were drawn using three representative measurements. Bars indicate
S.E.M. For total number of measurements and statistical data evaluation see Table 2. The corresponding peak current densities are shown in Table 3.
doi:10.1371/journal.pone.0019188.g002
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Channel Peak current densities (HEK293) Ipersistent/Itransient (610
23)
pA/pF n at 230 mV at 210 mV n
hNav1.5 271625 29 1161.9 2166.3 6
T1620K 254626 25 1762.9 2665.3 9
hNav1.5a 347648 16 861.4 1765.1 7
T1620Ka 282642 11 1361.4 2063.0 5
hNav1.5c 295628 35 1566.6 2067.3 11
T1620Kc 236618 38 2165.9 33611 6
hNav1.5d 110615* 33 n.d. n.d. -
T1620Kd 84611
1 29 n.d. n.d. -
hNav1.5e 194620* 11 23610 1662.1 5
T1620Ke 182623
1 10 961.4 1362.4 9
For measurements of persistent Na
+ currents, we used the Xenopus oocytesystemandundilutedcRNApreparations(,1–2 mg/ml)forinjectioninordertoincreasethissmall
current fraction. This resulted in transient Na
+ currents .10 mA in 96 mM external Na
+. In none of the channels investigated, a significant increase of the persistent current
fractioncould beobserved. Low expressionlevelsofhNav1.5dand T1620Kd didnot allowforanaccuratedetermination ofthepersistent currentfraction.Asa positivecontrol,
weusedcRNAfor DKPQ channels,thefirst known LQT3mutant.Respective values for Ipersistent/Itransientwere: 179642610
23 at230 mV,and 159627610
23 at210 mV(n=7).
*Indicates p,0.05 for a hNav1.5 splice variant versus hNav1.5.
1Indicates p,0.05 for a spliced T1620K variant versus T1620K.
#Indicates p,0.05 for a T1620K variant versus the corresponding hNav1.5 variant.
doi:10.1371/journal.pone.0019188.t003
Figure 3. Electrophysiological properties of spliced hNav1.5a and T1620Ka channels. Steady-state activation (A), time constants of
inactivation (B), steady-state inactivation (C) and recovery from inactivation (D) were indistinguishable in hNav1.5a and hNav1.5 (dotted). Mutation
T1620K produced similar defects in both the spliced and non-spliced (dashed) background (see Tables 2 and 3 for data evaluation and statistics).
doi:10.1371/journal.pone.0019188.g003
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+ currents
Determination of the persistent current fraction was done in
Xenopus laevis oocytes using the two-microelectrode voltage clamp
technique using a commercial amplifier (TEC-05-S; npi electronic
GmbH, Tamm, Germany), as previously described [29,36].
Briefly, Xenopus laevis oocytes were injected with undiluted cRNA
preparations (,1–2 mg/ml). The persistent current fraction was
determined as follows: First, we measured the inward current at
the end of a 200 ms test pulse that could be blocked by 10 mM
TTX in 96 mM external Na
+ (Ipersistent). Then, we reduced the
extracellular Na
+ concentration to 20 mM in order to insure
adequate voltage control also for the first few milliseconds of the
test pulse and determined the peak current amplitude in the same
oocyte (Itransient). Construction of the control plasmid encoding
DKPQ channels was previously described [29].
Results
First, we studied consequences of the T1620K mutation on
electrophysiological properties of non-spliced wild-type hNav1.5 in
HEK293 cells by the whole-cell patch-clamp technique (Fig. 1B).
We observed a negative shift of the mid-activation potential Vm
and of the mid-inactivation potential Vh by 24.5 mV and
210.9 mV, respectively (Table 2; Fig. 2). The slope factor of the
steady-state activation curve remained unchanged, whereas the
steady-state inactivation curve flattened significantly. Recovery
from inactivation was accelerated, which became apparent from
the shorter time constant tf. The most notable alteration was a
substantial loss of the voltage-dependency of the inactivation time
course (Fig. 2B), resulting in faster inactivation at hyperpolarized
potentials (negative to 240 mV) and in slower inactivation at
more depolarized potentials (positive to 240 mV). Peak current
density was not affected by the mutation, and an increased
persistent current fraction was not observed (Table 3). These data
on T1620K are in close agreement with our previous measure-
ments [29], when we used the original hH1 clone as the reference
cDNA for heterologous expression [30]. The hH1 sequence
corresponds to a very rare variation of hNav1.5: It codes for
Q1027, instead of the most commonly found R1027 variant [31].
Consequently, our data show that Q1027 and R1027 channels are
indistinguishable with respect to the effect of the T1620K
mutation.
Beside Q1027, the hH1 sequence encodes also the amino acid
Q1077. The additional CAG triplet is introduced by alternative
usage of the exon 18 splice acceptor site [31]. The CAG-inclusive
variant is considered as the splice variant Nav1.5c, because
Figure 4. Electrophysiological properties of spliced hNav1.5d and T1620Kd channels. Steady-state activation (A), time constants of
inactivation (B), steady-state inactivation (C) and recovery from inactivation (D). In hNav1.5d, the mid-activation potential was shifted towards
depolarized potentials, and it remained unchanged in T1620Kd (A). Recovery from inactivation was slower in hNav1.5d compared to hNav1.5; it was
further decelerated in T1620Kd (D). Note that the current densities were significantly reduced (Table 3), an effect that was largely due to a reduction
in open probability in hNav1.5d [34].
doi:10.1371/journal.pone.0019188.g004
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heart [31]. Electrophysiological properties of hNav1.5 and
hNav1.5c were virtually identical (Table 2). Moreover, the effect
of the T1620K mutation was independent of whether Q1077 was
absent (T1620K) or present (T1620Kc; Table 2). In both T1620K
and T1620Kc, the mid-activation and mid-inactivation potentials
were shifted towards hyperpolarized potentials, the slope factor of
the steady-state inactivation curve was increased, recovery from
inactivation was accelerated, and channel inactivation was less
voltage-dependent, when compared to hNav1.5 and hNav1.5c
(Table 2). The persistent current fraction was not increased
(Table 3).
Next we constructed splice variant hNav1.5a and the corre-
sponding mutant T1620Ka by deleting the exon 18 sequence in
the hNav1.5 and T1620K cDNAs, respectively. Similarly as found
for hNav1.5c, spliced Nav1.5a channels were indistinguishable
from hNav1.5. The introduction of mutation T1620K in the
hNav1.5a background, resulting in T1620Ka channels, produced
similar electrophysiological defects as observed in T1620K
channels (Fig. 3, Table 2). Together these data with T1620Ka
and T1620Kc suggested that the positively charged lysine at
position 1620 has a dominant effect on channel gating,
independently of whether or not the intracellularly located DII-
DIII linker is modified by alternative splicing (Fig. 1A).
However, when analyzing the effect of the T1620K mutation in
the background of hNav1.5d, a splice variant characterized by the
deletion of a short stretch within the DII-DIII linker (Fig. 1) [34],
we observed unexpected modulatory effects in the mutant splice
variant. In hNav1.5d, the deletion itself caused a positive shift of
steady-state activation by 8.9 mV, and a significantly decelerated
recovery from inactivation, when compared to full-length hNav1.5
channels (Table 2) [34]. In the corresponding mutant splice
variant T1620Kd, steady-state activation was not shifted towards
hyperpolarized potentials and the slope factor of this curve
increased significantly (Table 2, Fig. 4). Furthermore, in contrast
to the accelerating effect of the T1620K mutation on recovery
from inactivation in the other splice variants, the recovery time
constant tf was increased in T1620Kd, when compared to splice
variant hNav1.5d (Table 2, Fig. 4). When compared to T1620K,
also the recovery from slow inactivation was decelerated in
T1620Kd, which became apparent from the larger time constant
ts and the increased amplitude As (Table 2). Consistent with
enhanced entry into the slow-inactivated state, we found most
negative V1/2 values for steady-state slow inactivation in T1620Kd
(284.363.1 mV), compared to hNav1.5d (276.165.7 mV),
T1620K (269.164.2 mV), and hNav1.5 (260.062.0 mV)
(Fig. 5). At membrane potentials between 2100 mV and
270 mV, a significantly larger fraction of T1620Kd channels
underwent slow inactivation, when compared to the other three
types of channels (asterisks in Fig. 5). This indicates that alternative
splicing of the mutant channel variant creates an additional loss-of-
function feature that could be of physiological relevance at the
resting membrane potential. In conclusion, effects of the T1620K
mutation in the background of hNav1.5d were different from those
observed with mutated hNav1.5, hNav1.5a, and hNav1.5c
channels.
In splice variant hNav1.5e, the first of two tandemly arranged
exon 6 sequences, neonatal exon 6a, is incorporated into the final
transcript (Fig. 1A). Electrophysiological properties of hNav1.5e
channels were different from those of hNav1.5 (Table 2, Fig. 6).
We observed a pronounced shift of steady-state activation towards
depolarized potentials by 10.1 mV in hNav1.5e, and reduced peak
current densities (Tables 2 and 3). Thus, electrophysiological
properties of splice variant hNav1.5e were similar to those of
hNav1.5d. However, unlike T1620Kd, the mutation at position
1620 caused a hyperpolarizing shift of steady-state activation and a
faster recovery from inactivation in T1620Ke (Fig. 6A). Thus,
T1620Ke channels show steady-state activation properties that are
distinct from all other channel types investigated in this study.
Steady-state inactivation and recovery from inactivation were
similarly affected in T1620Ke, when compared to T1620K
(Fig. 6C and D), and there was no increase of the persistent
current (Table 3).
In conclusion, alternative splicing of hNav1.5 creates different
wild-type and mutant channels. Statistical evaluation revealed a
rather broad channel variability in case of the steady-state
activation parameters and inactivation time constants (Table 2).
Steady-state inactivation data were similar among all hNav1.5
variants as well as among all mutated channels. Recovery from
inactivation was accelerated in most of the mutant channels,
except for T1620Kd channels (Fig. 4D). When considering only
the relative alterations of the mid-activation potential Vm, the mid-
inactivation potential Vh and the recovery time constant tf,
mutation T1620K produced similar effects in the background of
most splice variants (Fig. 7). In T1620Kd, however, Vm remained
unchanged, and even an opposite effect on the recovery from
inactivation was observed.
Discussion
In the present study we systematically investigated electrophys-
iological properties of mutant T1620K channels in the back-
ground of all known functional Nav1.5 splice variants. We found
that alternative splicing is a potential mechanism that allows
generating a variety of functionally distinct wild-type and mutant
hNav1.5 channels.
Figure 5. Steady-state slow inactivation. We first applied test pulsesof
500 ms to achieve entry into the slow-inactivated state, followed by a short
interval (20 ms) at 2120 mV to allow only recovery from fast inactivation.
Currents were recorded using a second test pulse to 0 mV and plotted
a g a i n s tt h ep o t e n t i a lo ft h ef i r s tt e s tp u l se. Asterisks indicate significantly
enhanced entry into the slow-inactivated state in T1620Kd channels versus
hNav1.5d, hNav1.5, and T1620K channels. Bars indicate S.E.M.
doi:10.1371/journal.pone.0019188.g005
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hNav1.5 in the heart and in other tissues is currently not fully
understood [28]. Consequently, and this is a major limitation of
the present study, we can only speculate on the function of
alternative splicing in SCN5A channelopathies, in particular on
the role of the functional T1620K splice variants for cardiac
excitability in our patients. Recently, it became evident that
alternative splicing of Nav1.5 is strictly species-dependent [2]. For
example, Nav1.5a was not detected in the adult non-diseased
human heart so far. Furthermore, there is still little information
on the expression level and function of all five functional hNav1.5
variants in different heart regions, at distinct ontogenetic stages,
and in the diseased myocardium. Moreover, most of these splice
variants were detected by RT-PCR only, but so far not by
independent RNA or specific protein detection methods, like
RNase protection assays or Western blotting, respectively. Except
for Nav1.5e [37], specific antibodies do not exist. Shorter RT-
PCR products can also result from intramolecular template
switching by reverse transcriptases during cDNA preparation
[38,39]. Such PCR products were frequently misinterpreted in
the literature as alternative transcripts [38,39]. The pronounced
tissue-, age- and species-dependent occurrence of shorter hNav1.5
cDNA variants suggest that they are indeed the result of
alternative splicing and that the proteins are produced in vivo,
but an artifactual RT-PCR ‘‘splicing’’ cannot be fully excluded
[28].
Nav1.5a is thought to be one of the major alternatively spliced
Nav1.5 variants in the heart of small rodents [2,28]. It has been
also observed in several other tissues of rats and mice, such as
dorsal root ganglia, brain or neuronal progenitor cell lines.
Electrophysiological properties of hNav1.5a were indistinguishable
from those of authentic hNav1.5, and gating of both channels was
similarly affected by the threonine-lysine exchange at position
1620 (Figs. 3 and 7). These data suggest that, if this splice variant is
produced in the human heart at all, it would not be of
pathophysiological relevance for T1620K carriers.
Similar data were obtained for hNav1.5c, the major Nav1.5
splice variant in the human heart [31], and for the corresponding
splice variant T1620Kc. Noteworthy, the effect of Q1077 on
electrophysiological properties of mutant channels has been
already investigated by other groups and, depending on the
background sequence, differential effects were observed [19,20].
For example, three missense variants of hNav1.5, identified in a
SIDS cohort (delAL586-587, R680H, and V1951L), generated an
increased persistent current only in the hNav1.5 background
(delQ1077), but not in the Q1077-inclusive variant hNav1.5c [20].
These data suggest that deletion of Q1077 contributes to a
disturbed open-state inactivation in mutant channels, as long as
intracellularly located positions are affected. Position 1620 is
located in an extracellular linker region and the fraction of the
persistent current was neither increased in the hNav1.5 nor in
hNav1.5c background (Table 3).
Figure 6. Electrophysiological properties of spliced hNav1.5e and T1620Ke channels. Steady-state activation (A), time constants of inactivation
(B), steady-state inactivation (C) and recovery from inactivation (D). In the neonatal variant hNav1.5e, the mid-activation potential was shifted towards
depolarized potentials, similarly as found for splice variant hNav1.5d. Mutation T1620K caused a hyperpolarized shift of the steady-state activation.
doi:10.1371/journal.pone.0019188.g006
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e19188Nav1.5d is virtually absent in the heart of mice, rats, dogs, and
pigs [2]. This variant was so far detected only in RNA
preparations from the human heart, where it accounts for less
than 3% of the total cardiac Na
+ channel transcript pool
[2,28,34]. Mutation T1620K resulted in unexpected effects in
the hNav1.5d background. Our data suggested that the short
amino acid stretch, encoded by exon 17, is crucial for the
function of the extracellular DIV/S3S4 linker. In contrast to the
other mutant variants, mid-activation potential remained
unchanged, recovery from inactivation was decelerated and
steady-state slow inactivation was facilitated (Fig. 7). The latter
effect was specific for voltages around the resting membrane
potential (Fig. 5). These changes in kinetics in T1620Kd
compared to T1620K would minimize three potential gain-of-
function mechanisms expected to play a crucial role in LQT3:
First, the window current in T1620Kd should be nearly absent.
Respective steady-state activation and inactivation parameters
suggest that the overlap between both curves is even less
pronounced than that found for wild-type hNav1.5 (Table 2).
Second, recovery from inactivation was accelerated in T1620K
and in many other LQT3 mutant channels [5], leading to
facilitated channel reopening during the repolarization phase of
the cardiac action potential [40]. In case of T1620Kd, such an
effect can be excluded, because recovery from inactivation was
even decelerated. And third, peak current densities were
significantly smaller. A lower expression would counteract any
of the potential gain-of-function mechanisms in LQT3. Conse-
quently, T1620Kd channels are unlikely to contribute signifi-
cantly to prolonged QTc values. Actually, mutant T1620Kd
channels show most pronounced loss-of-function among all
T1620K variants investigated in this study. Thus, cardiac
conduction should be slower. In particular, the facilitated entry
into the slow inactivated state and reduced current densities are
features frequently found in hNav1.5 mutant channels leading to
CCD. In summary, it can be stated that, if this splice variant is
expressed in the heart, T1620Kd channels would counteract
QTc prolongation, but would also worsen cardiac conduction.
The latter effect would be particularly important, if hNav1.5d is
specifically expressed in the cardiac conduction system, which
was previously hypothesised [34].
Nav1.5e, also called neonatal Nav1.5 or nNav1.5, is strongly
expressed in neonatal mouse heart, but significantly down-
regulated during development [37]. Our data with hNav1.5e
and T1620Ke suggest that the switch from neonatal to adult exon
6 results in an improved cardiac excitability. In the adult variants,
hNav1.5 and T1620K, peak current densities increased and
steady-state activation was shifted towards hyperpolarized poten-
tials. The latter effect is likely associated with an increased window
current, contributing to QTc prolongation. Although the expres-
sion of Nav1.5e in the neonatal human heart has not yet been
confirmed, it is interesting to speculate that SCN5A mutations,
associated with sudden infant death syndrome (SIDS), may
provoke more severe channel defects when the neonatal exon 6
is replaced by the adult variant after birth. Furthermore, clinically
relevant mutations may be even introduced or replaced by a non-
mutated sequence when one of the exon 6 variants itself is affected.
Moreover, it is interesting to note that Nav1.5e is expressed in
human neuroblastoma [33] and in highly metastatic human breast
cancer cell lines [32]. Nav1.5e was also up-regulated in human
breast cancer biopsy tissues, and a strong correlation was found
between Nav1.5e expression and clinically assessed lymph node
metastasis [32]. Assuming that hNav1.5e is essential for the
enhancement of migration and invasion [32,41,42], SCN5A loss-of-
function mutations should exert protective effects against some
types of cancer.
In conclusion, alternative splicing generates a variety of
functionally distinct wild-type hNav1.5 and mutant T1620K
channels. The cellular splicing machinery should be considered
as a potential player affecting genotype-phenotype correlations. At
the same time we have to notice that conclusions with respect to
the physiological significance from our results for this distinct
SCN5A channelopathy are still restricted by our yet limited
knowledge on cell-specific and age-dependent generation of splice
variants in the normal and diseased human myocardium.
Figure 7. Relative alterations of mid-activation potentials Vm,
mid-inactivation potentials Vh, and recovery time constants tf.
Mutation T1620K caused similar shifts in the background of most splice
variants, except for hNav1.5d. Bars indicate S.E.M.
doi:10.1371/journal.pone.0019188.g007
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